Ann: CardieX Half Year Sales and Corporate Update, page-31

Seeing other biotechs drop in price today due to insufficient evidence of treating disease reinforces the importance of risk management in the sector. We have all invested in a biotech that’s already proven to help change peoples’ lives in a hospital setting. This patented, world first will soon hit the retail market in the form of a CardieX/Mobvoi smart watch which will be released in a few months and looks to produce a seven figure revenue (which explains how the new quality recruits will be paid).


I echo the words of our CEO that this is the most undervalued company listed on the ASX. The register is now tight after heavy selling and the stock is in the hands of the believers. Next year will be a big one and I’m confident we will all be rewarded.



I consider the SPP a “thank you” gift for our patience. The recent recruits indicate something big is at play and that it’s not too far away.